肝糖原贮积病患儿生玉米淀粉应用与消化道并发症的横断面调查
该横断面研究基于广东省人民医院343例基因确诊的肝GSD患儿,于2024年7月和2025年7月进行标准化问卷调查。结果显示UCCS日均摄入量为5.8(3.6,8.0)g/kg,高剂量组消化道症状评分高于低剂量组,UCCS摄入量是消化道症状的独立风险因素(OR=1.12,P=0.006)。患儿同时面临生长迟缓和超重或肥胖的双重营养挑战。
要点
- UCCS摄入量与消化道症状呈剂量-效应关系,是独立风险因素(OR=1.12)。
- 生长迟缓总体发生率20.6%,超重或肥胖18.1%,需兼顾营养双面问题。
- Ⅰa和Ⅰb型代谢紊乱最突出,UCCS摄入量也最高。
核心结论
- 肝GSD患儿临床异质性显著,UCCS摄入量与消化道症状负担呈明确剂量-效应关系。
- 患儿面临生长迟缓与超重或肥胖的双重营养挑战,临床需关注UCCS耐受性及亚型管理。
研究设计与样本
- 横断面调查,依托广东省人民医院糖原贮积病队列。
- 于2024年7月和2025年7月分2次对343例经基因确诊的肝GSD患儿进行标准化问卷调查。
- 收集人口学、基因亚型、临床特征、UCCS应用、消化道症状及实验室检测数据。
- 根据基因亚型、年龄及UCCS日均摄入中位数分组,采用WHO标准HAZ和BMIZ评估生长发育及营养状态。
- 采用二元及有序Logistic回归分析UCCS摄入量对消化道症状风险的影响。
主要发现
- 343例中Ⅰa型138例、Ⅰb型75例、Ⅲ型55例、Ⅳ型3例、Ⅵ型24例及Ⅸ型48例。
- 高乳酸血症Ⅰa型占89.9%(124/138)、Ⅰb型占94.7%(71/75);高甘油三酯血症Ⅰa型占75.4%(104/138)、Ⅰb型占62.7%(47/75)。
- 166例(48.4%)患儿在过去1个月内至少出现一种消化道症状。
- UCCS日均摄入量5.8(3.6,8.0)g/kg,Ⅰa型7.0(4.6,8.8)g/kg和Ⅰb型6.6(4.3,9.2)g/kg最高。
- 高剂量组(168例)消化道症状评分1(0,1)分高于低剂量组(175例)0(0,1)分,P<0.001。
关键数值与推荐
- 控制年龄、性别、BMI后,UCCS摄入量是消化道症状的独立风险因素(OR=1.12,P=0.006)。
- UCCS日摄入量是厌食、腹泻、恶心呕吐3种症状的独立风险因素(均P<0.05)。
- 生长迟缓(HAZ<-2 s)总体发生率20.6%(66/320),Ⅰb型38.8%(26/67)和11~18岁组37.9%(22/58)占比最高。
- 超重或肥胖(BMIZ>+2 s)总体发生率18.1%,0~3岁组22.7%(22/97)和Ⅰa型22.7%(29/128)最突出。
临床怎么用
- 临床需关注肝GSD患儿UCCS摄入的个体耐受性,平衡血糖控制与肠道健康。
- 应针对不同基因亚型采取特异性管理策略,兼顾生长发育监测。
- 对UCCS高剂量摄入患儿需警惕厌食、腹泻、恶心呕吐等消化道症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical characteristics and current utilization of uncooked cornstarch (UCCS) in children with hepatic glycogen storage disease (GSD), so as to investigate the association between UCCS intake and gastrointestinal (GI) complications. Methods: A cross-sectional study was conducted using the GSD cohort at Guangdong Provincial People's Hospital. Standardized questionnaire surveys were administered in July 2024 and July 2025 among 343 genetically confirmed pediatric patients with hepatic GSD. Data included demographic information, genetic subtypes, clinical features, UCCS intake regimens, GI symptoms and laboratory findings were collected. Participants were stratified by genetic subtype, age group, and median daily UCCS intake. Growth and nutritional status were evaluated according to World Health Organization (WHO) growth standards, using height-for-age Z-scores (HAZ) and BMI-for-age Z-scores (BMIZ) across age groups and genetic subtypes. Clinical manifestations, laboratory parameters, UCCS intake regimens, and the prevalence of GI symptoms were compared across genetic subtypes. The burden of GI symptoms was quantified using a severity score (ranging from 0 to 3), assigned based on the presence and number of reported symptoms. Between-group comparisons were performed using the Mann-Whitney U test. Binary and ordinal Logistic regression models were employed to assess the association between UCCS intake and the risk or severity of GI symptoms. Results: Among the 343 enrolled patients, the distribution by genetic subtype was as follows: 138 with type Ⅰa, 75 with type Ⅰb, 55 with type Ⅲ, 3 with type Ⅳ, 24 with type Ⅵ, and 48 with type Ⅸ. Distinct inter-subtype differences in clinical presentation were observed. Metabolic disturbances were most pronounced in types Ⅰa and Ⅰb: hyperlactatemia was highly prevalent in type Ⅰa (124/138, 89.9%) and type Ⅰb (71/75, 94.7%), and hypertriglyceridemia was common in type Ⅰa (104/138, 75.4%) and type Ⅰb (47/75, 62.7%). A total of 166(48.4%) children reported at least one GI symptom during the preceding month. Daily UCCS intake was 5.8 (3.6, 8.0) g/kg, with the highest intakes observed in subtype Ⅰa (7.0 (4.6, 8.8) g/kg) and subtype Ⅰb (6.6 (4.3, 9.2) g/kg). The GI symptom score in the high-dose group (168 cases) was higher than that in the low-dose group (175 cases)(1 (0,1) vs.0 (0,1), P<0.001). After adjustment for age, sex, and body mass index (BMI), UCCS intake remained an independent risk factor for GI symptoms (OR=1.12, P=0.006). Daily UCCS intake was also independently associated with anorexia, diarrhea, and nausea/vomiting (all P<0.05). Growth assessment revealed an overall stunting prevalence (HAZ<-2 s) of 20.6% (66/320), with the highest rates observed in subtype Ⅰb (38.8%, 26/67) and 11-18 years group (37.9%, 22/58). The overall prevalence of overweight or obesity (BMIZ>+2 s) was 18.1%, most notably elevated among 0-3 years group (22.7%, 22/97) and in subtype Ⅰa (22.7%, 29/128). Conclusions: Children with hepatic GSD exhibit marked clinical heterogeneity across subtypes. A clear dose-response relationship demonstrate between UCCS intake and GI symptom burden. Moreover, these patients face a dual nutritional challenge of stunting and overweight or obesity. In clinical practice, careful attention should be paid to individual UCCS tolerance and subtype-specific management strategies, balancing glycemic control, intestinal health, optimal growth and development. 目的: 评估肝糖原贮积病(GSD)患儿的临床特征及生玉米淀粉(UCCS)应用现状,明确UCCS摄入量对消化道并发症发生风险的影响。 方法: 横断面调查。依托广东省人民医院糖原贮积病队列,于2024年7月和2025年7月分2次对经基因确诊的343例肝GSD患儿进行标准化问卷调查,收集其人口学、基因亚型、临床特征、UCCS应用、消化道症状及实验室检测数据。根据基因亚型、年龄及UCCS日均摄入中位数分组,采用世界卫生组织标准中年龄的身高Z评分(HAZ)和年龄的体质指数Z评分(BMIZ)评估不同年龄及亚型患儿生长发育及营养状态;分析各亚型的临床表现、实验室指标、UCCS摄入量及消化道症状发生率;按消化道症状有无计分(0~3分)评估消化道的症状负担,组间比较采用Mann-Whitney U检验;采用二元及有序Logistic回归分析UCCS摄入量对消化道症状风险的影响。 结果: 343例中Ⅰa型138例、Ⅰb型75例、Ⅲ型55例、Ⅳ型3例、Ⅵ型24例及Ⅸ型48例。各亚型临床特征各有差异:Ⅰa型和Ⅰb型的代谢紊乱最突出,高乳酸血症[Ⅰa型占89.9%(124/138)、Ⅰb型占94.7%(71/75)]与高甘油三酯血症[Ⅰa型占75.4%(104/138)、Ⅰb型占62.7%(47/75)]较常见。166例(48.4%)的患儿在过去1个月内至少出现一种消化道症状。UCCS日均摄入量5.8(3.6,8.0)g/kg,Ⅰa和Ⅰb型最高,分别为7.0(4.6,8.8)与6.6(4.3,9.2)g/kg。高剂量组(168例)的消化道症状评分1(0,1)分高于低剂量组(175例)0(0,1)分,差异有统计学意义(P<0.001)。控制年龄、性别、体质指数后,UCCS摄入量是消化道症状的独立风险因素(OR=1.12,P=0.006)。UCCS日摄入量是厌食、腹泻、恶心呕吐3种症状的独立风险因素(均P<0.05)。生长发育评估显示,生长迟缓(HAZ<-2 s)总体发生率20.6%(66/320),以Ⅰb型[38.8%(26/67)]和11~18岁[37.9%(22/58)]占比最高。超重或肥胖(BMIZ>+2 s)总体发生率18.1%,以0~3岁[22.7%(22/97)]和Ⅰa型[22.7%(29/128)]最为突出。 结论: 肝GSD患儿临床异质性显著,UCCS摄入量与消化道症状呈明确剂量-效应关系且面临生长迟缓与超重或肥胖的双重挑战。临床需关注UCCS耐受性及亚型管理,兼顾血糖、肠道与生长发育。.
引用
- Wen Y, Jing JY, Zhang XY, et al. [A cross-sectional survey on uncooked corn starch application and gastrointestinal complications in children with hepatic glycogen storage disease]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42298849. doi:10.3760/cma.j.cn112140-20251223-01132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。